BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Overview of attention for article published in Clinical Epigenetics, November 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 24 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics

Wall Street Online Denmark, 12 Nov 2020

CALGARY, Alberta, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.